Prednisolone Solution
NDC Package 0121-0885-16

11-digit billing NDC: 00121088516 · Billing unit: ML · 480 ML per package

Package Information

Prednisolone solution is prednisolone Oral Solution USP is indicated in the following conditions:1. This formulation utilizes a solution delivery system. Marketed by Pai Holdings, Llc Dba Pai Pharma, this product is identified by NDC 0121-0885 and is authorized under FDA application ANDA040571.

Identification & Billing

NDC Package Code
0121-0885-16
Package Description
480 mL in 1 BOTTLE
Product Code
11-Digit Billing Format
00121088516
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Units Per Package
480 ML
RxNorm Crosswalk
  • RxCUI: 283077 - prednisoLONE sodium phosphate 15 MG in 5 mL Oral Solution
  • RxCUI: 283077 - prednisolone 3 MG/ML Oral Solution
  • RxCUI: 283077 - prednisolone 15 MG (as prednisolone sodium phosphate 20.2 MG) per 5 ML Oral Solution
  • RxCUI: 283077 - prednisolone 15 MG per 5 ML Oral Solution

Clinical Specifications

Proprietary Name
Prednisolone
Non-Proprietary Name
Prednisolone
Substance Name
Prednisolone
Dosage Form
Solution - A clear, homogeneous liquid1 dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Prednisolone Oral Solution USP is indicated in the following conditions:1. Endocrine Disorders      Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice:  synthetic analogs may be used in conjunction with mineralocorticoids where applicable:  in infancy mineralocorticoid supplementation is of particular importance).            Congenital adrenal hyperplasia            Nonsuppurative thyroiditis            Hypercalcemia associated with cancer2. Rheumatic Disorders      As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:            Psoriatic arthritis            Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)            Ankylosing spondylitis            Acute and subacute bursitis            Acute nonspecific tenosynovitis            Acute gouty arthritis            Post-traumatic osteoarthritis            Synovitis of osteoarthritis            Epicondylitis3. Collagen Diseases      During an exacerbation or as maintenance therapy in selected cases of:            Systemic lupus erythematosus            Acute rheumatic carditis4. Dermatologic Diseases            Pemphigus            Bullous dermatitis herpetiformis            Severe erythema multiforme (Stevens-Johnson syndrome)            Exfoliative dermatitis            Mycosis fungoides            Severe psoriasis            Severe seborrheic dermatitis5. Allergic States      Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:            Seasonal or perennial allergic rhinitis            Bronchial asthma            Contact dermatitis            Atopic dermatitis            Serum sickness            Drug hypersensitivity reactions6. Ophthalmic Diseases      Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:            Allergic corneal marginal ulcers            Herpes zoster ophthalmicus            Anterior segment inflammation            Diffuse posterior uveitis and choroiditis            Sympathetic ophthalmia            Allergic conjunctivitis            Keratitis            Chorioretinitis            Optic neuritis            Iritis and Iridocyclitis7. Respiratory Disorders            Symptomatic sarcoidosis            Loeffler’s syndrome not manageable by other means            Berylliosis            Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy            Aspiration pneumonitis8. Hematologic Disorders            Idiopathic thrombocytopenic purpura in adults            Secondary thrombocytopenia in adults            Acquired (autoimmune) hemolytic anemia            Erythroblastopenia (RBC anemia)            Congenital (erythroid) hypoplastic anemia9. Neoplastic Diseases      For palliative management of:            Leukemias and lymphomas in adults            Acute leukemia of childhood10. Edematous States      To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.11. Gastrointestinal Diseases      To tide the patient over a critical period of the disease in:            Ulcerative colitis            Regional enteritis12. Miscellaneous      Tuberculous meningitis with subarachnoid block or impending block used concurrently with appropriate antituberculous chemotherapy.  Trichinosis with neurologic or myocardial involvement.In addition to the above indications, Prednisolone Oral Solution USP is indicated for systemic dermatomyositis (polymyositis).

Regulatory & Marketing

Labeler Name
Pai Holdings, Llc Dba Pai Pharma
Product Type
Human Prescription Drug
FDA Application #
ANDA040571
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
09-12-2023
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

Source: ASP
Prednisolone oral per 5 mg
HCPCS Dosage 5 MG
Units / Pkg 288

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0121-0885). Click a package code to view its specific billing and regulatory data.

240 mL in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0121-0885-16 identifies a specific commercial package of 480 ml in 1 bottle of Prednisolone, a human prescription drug labeled by Pai Holdings, Llc Dba Pai Pharma. This solution is formulated for oral use and contains prednisolone as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Pai Holdings, Llc Dba Pai Pharma on September 12, 2023. The current certification is valid through December 31, 2027.

How is this Pai Holdings, Llc Dba Pai Pharma product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00121088516. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 480 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0121-0885-16
11-Digit CMS (5-4-2)
00121-0885-16

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.